Robert K Flamm

Summary

Affiliation: Focus Technologies
Country: USA

Publications

  1. pmc Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002
    Robert K Flamm
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 48:2431-6. 2004
  2. pmc Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci
    Virginia D Shortridge
    Discovery and Clinical Microbiology, Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:783-6. 2002
  3. pmc Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 52:1510-2. 2008
  4. ncbi request reprint Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens
    Angela M Nilius
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, IL 60064 3537, USA
    J Antimicrob Chemother 49:831-6. 2002
  5. ncbi request reprint Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus
    Laurel S Almer
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, IL, USA
    Diagn Microbiol Infect Dis 43:225-32. 2002
  6. pmc In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457
    Barbara D Foleno
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 51:361-5. 2007
  7. ncbi request reprint Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae
    Zhensheng Cao
    Dept R42A, Infectious Disease Research, Bldg AP30, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064 6145, USA
    Int J Antimicrob Agents 24:362-8. 2004
  8. pmc In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms
    Laurel S Almer
    Infectious Diseases Research, R47T, AP52N, Abbott Laboratories, Abbott Park, IL 60064 3537, USA
    Antimicrob Agents Chemother 48:2771-7. 2004
  9. ncbi request reprint Emergence of macrolide resistance during treatment of pneumococcal pneumonia
    Daniel M Musher
    N Engl J Med 346:630-1. 2002
  10. ncbi request reprint Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations
    Stella Z Doktor
    Infectious Diseases Research, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    Diagn Microbiol Infect Dis 49:47-52. 2004

Detail Information

Publications13

  1. pmc Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002
    Robert K Flamm
    Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171 4603, USA
    Antimicrob Agents Chemother 48:2431-6. 2004
    ..Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%)...
  2. pmc Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci
    Virginia D Shortridge
    Discovery and Clinical Microbiology, Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Antimicrob Agents Chemother 46:783-6. 2002
    ..06 microg/ml; telithromycin MIC90, 0.5 microg/ml). ABT-773 has superior activity against macrolide-resistant streptococci compared to that of telithromycin...
  3. pmc Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa
    Todd A Davies
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 52:1510-2. 2008
    ..This PBP affinity profile correlates with the broad-spectrum gram-negative activity observed with doripenem...
  4. ncbi request reprint Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens
    Angela M Nilius
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, IL 60064 3537, USA
    J Antimicrob Chemother 49:831-6. 2002
    ..The susceptibility profiles indicate that different mutations were selected and that ABT-773 and erythromycin may interact with the ribosome differently...
  5. ncbi request reprint Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus
    Laurel S Almer
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, IL, USA
    Diagn Microbiol Infect Dis 43:225-32. 2002
    ..Our results indicate that MRSA from adult subjects with community respiratory infections have similar antimicrobial susceptibility profiles and resistance mechanisms as nosocomial MRSA, and represent a genetically diverse group...
  6. pmc In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457
    Barbara D Foleno
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 51:361-5. 2007
    ..Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid...
  7. ncbi request reprint Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae
    Zhensheng Cao
    Dept R42A, Infectious Disease Research, Bldg AP30, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064 6145, USA
    Int J Antimicrob Agents 24:362-8. 2004
    ..Therefore, the tight binding of cethromycin with ribosomes likely contributed to the faster drug accumulation, slower dissociation from cells and prolonged molecular PAE of cethromycin for H. influenzae...
  8. pmc In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms
    Laurel S Almer
    Infectious Diseases Research, R47T, AP52N, Abbott Laboratories, Abbott Park, IL 60064 3537, USA
    Antimicrob Agents Chemother 48:2771-7. 2004
    ..Bactericidal activity of ABT-492 was also evaluated...
  9. ncbi request reprint Emergence of macrolide resistance during treatment of pneumococcal pneumonia
    Daniel M Musher
    N Engl J Med 346:630-1. 2002
  10. ncbi request reprint Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations
    Stella Z Doktor
    Infectious Diseases Research, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    Diagn Microbiol Infect Dis 49:47-52. 2004
    ..50s ribosomal mutations are the least frequent mechanism of S. pneumoniae resistance, occurring at an extremely low frequency and are identified only by genome sequence data...
  11. pmc Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci
    Daniel J Diekema
    Department of Internal Medicine, University of Iowa Colleges of Medicine and Public Health, Iowa City, Iowa 52242, USA
    J Clin Microbiol 41:2659-61. 2003
    ..Erm methylase (ermA and ermB) was the most common resistance mechanism detected, present in 12 of 20 macrolide-resistant GBS...
  12. ncbi request reprint Fluoroquinolone resistance in Streptococcus pyogenes
    Sandra S Richter
    Department of Pathology, University of Iowa Healthcare, Iowa City, Iowa 52242, USA
    Clin Infect Dis 36:380-3. 2003
    ..This is the second report of a clinical isolate of S. pyogenes with high-level fluoroquinolone resistance...
  13. pmc In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone
    Angela M Nilius
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064 3537, USA
    Antimicrob Agents Chemother 47:3260-9. 2003
    ....